Head and Neck Cancer Clinical Trial
Official title:
A Korean Post Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck (SCCHN)
After consultation with the Korean Health Authorities, the two Post-Authorization Safety
Studies EMR 62202-509 (NCT01082315) and EMR 62241-508 (NCT01075828) were combined within one
study protocol EMR 062202-551. This Post-Marketing Surveillance Study (PMS) EMR 062202-551
is requested by the Korean Health Authorities to continue monitoring of Erbitux and provide
further information about safety and toxicity in clinical practice in at least 900 patients
during 6 years.
All data points from the EMR 62202-509 (NCT01082315) and EMR 62241-508 (NCT01075828) remain
unchanged in protocol EMR 062202-551. Therefore, the Sponsor has decided not to separately
disclose the EMR 062202-551 study titled "A Korean Post-Marketing Surveillance Study On
Erbitux® (Cetuximab) in Patients With Locally Advanced or Recurrent and/or Metastatic
Squamous Cell Cancer of the Head and Neck (originally EMR 62241-508) and in Patients With
EGFR-expressing, KRAS wild-type Metastatic Colorectal Cancer (originally EMR 62202-509)" on
clinicaltrials.gov.
This is a prospective, Post Marketing Surveillance (PMS) study on Erbitux® (Cetuximab) in
patients with locally advanced or recurrent and/or metastatic squamous cell cancer of the
head and neck in Korea
This prospective study will collect safety information from more than 300 subjects treated
with Erbitux as final evaluable cases. During the PMS period, subject background, subject's
medical (surgery, anti-cancer treatment) history, Erbitux treatment status, concurrent
medication, response evaluation, status and reason of discontinuation, all adverse events
(AEs; regardless of the causal relationship to Erbitux), and abnormal results of laboratory
tests will be collected for the study purpose.
The PMS is based on all cases treated with Erbitux at least once. The PMS will be done
within 6 years from the approval date of the new indication. This PMS is requested by the
Korean Regulatory Authorities. After approval of new indication in Korea, it is further
required to investigate more than 300 subjects during 6 years according to local regulations
to continue monitoring and provide further information about safety and toxicity in clinical
practice.
OBJECTIVES Analysis on safety and efficacy information on the use of Erbitux in the market
and factors affecting its safety and efficacy.
Primary objective:
- To obtain safety information on the use of Erbitux in subjects with locally advanced
SCCHN or recurrent and/or metastatic in terms of frequency and severity of AEs
Secondary objectives:
- To gather clinical efficacy information of the treatment
;
Observational Model: Case-Only, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05808920 -
The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03997643 -
Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04700475 -
Effect of Low Level Laser Therapy on Prevention of Radiotherapy Induced Xerostomia in Cancer Patients.
|
N/A | |
Withdrawn |
NCT04058145 -
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT02572869 -
Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
|
||
Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05073809 -
Photoacoustic Imaging of Head and Neck Tumours
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT03651570 -
Randomized Controlled Trial of a E-intervention to Help Patients Newly Diagnosed With Cancer Cope Better: Pilot Study
|
N/A | |
Recruiting |
NCT04930432 -
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06016699 -
Immunological Function After Radiation With Either Proton or Photon Therapy
|
||
Terminated |
NCT03843554 -
Commensal Oral Microbiota in Head and Neck Cancer
|
N/A | |
Recruiting |
NCT05915572 -
Mulligan Technique on Shoulder Dysfunction
|
N/A | |
Completed |
NCT05897983 -
Tens and Rocabado Exercises on TMJ Dysfunction
|
N/A | |
Not yet recruiting |
NCT06289049 -
Heavy Strength Training in Head and Neck Cancer Survivors
|
Phase 2 | |
Withdrawn |
NCT05263648 -
Virtual Reality Software to Reduce Stress in Cancer Patients
|
N/A | |
Withdrawn |
NCT03238638 -
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
|
Phase 2 |